News

First victim of the Alaskapox Virus highlights the need for increased research.

GSK’s bepirovirsen received this designation, and the company has its sights on the therapy potentially providing a functional cure for the millions of people around the world who are affected by this form of viral hepatitis.

Increased risk of post-acute conditions (PASC) in SARS-CoV-2 positive patients.

This month is a time to reflect on the past, but understand there remains issues that need to be addressed today.

Study offers new insight into the relationship between Zika Virus and Dengue Virus in tropical regions.

A recent study reveals the QIV-HD vaccine significantly lowers hospitalization rates compared to the standard-dose vaccine (QIV-SD).

HCV seroprevalence and antigen positivity were both low, suggesting universal birth cohort screening may not be necessary or cost-effective.

Inhaled nanoparticles deliver antibiotic and antimicrobial peptides through mucus and biofilm barriers in animal model of infection-exacerbated COPD.

In a case report, a patient with HIV with active multiple sclerosis showed reduced disease activity with tenofovir-containing antiretrovirals, suggesting potential MS treatment benefits.

This week, a study advocates enhancing hospital cleaning protocols to halt healthcare-associated infections; integrating HCV testing and antivirals in prisons to cut transmission of the disease; FDA announces listeria outbreak that leads to deaths and hospitalizations across 11 US states; CDC makes advances in foodborne outbreak detection via genome sequencing; and new data about the self-amplifying mRNA vaccine, ARCT-154.

Phase 3 trial is highly effective in preventing symptomatic disease.

Phase 3 study reveals exebacase combined with standard antibiotics in treating methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis did not meet its primary endpoints.

The self-amplifying mRNA vaccine, ARCT-154, had an extended response compared to the BNT162b2 vaccine and was approved in Japan back in November.

Study sheds light on the evolving landscape of HIV-related mortality since the advent of antiretroviral therapy (ART).

CDC endorses the role of antiviral drugs in combating COVID-19.

The outbreak has seen 2 deaths and 23 hospitalizations across 11 states.

Study encourages enhancing protocols to clean and disinfect hospital beds and healthcare environments to stop the spread of healthcare-associated infections.

CDC's use of it and power law analysis have greatly enhanced the detection and understanding of US foodborne outbreaks.

Phase 2 study for the investigational antiviral, ZSP1273 (onradivir), demonstrated safety and efficacy in reducing the time to resolution of symptoms in a multicenter trial.

Combating hepatitis C (HCV) transmission through integrated testing and enhanced use of direct-acting antivirals within the prison system can reduce incidence rates.

A study compared COVID-19 vaccination rates and found people with HIV (PWH) had a lower rate of completing the primary vaccination series.

ePOCT+, a digital clinician decision support tool, reduced outpatient antibiotic prescribing without adverse health outcomes, potentially mitigating development of antimicrobial resistance.

Study will determine the effectiveness of vaccine in preventing invasive pneumococcal disease.

Sustained virologic response (SVR) and sociodemographic factors were found to be associated with long-term improvements in health-related quality of life in patients with hepatitis C (HCV).

The fungal infection includes 4 patients, but so far no deaths are associated with it.

This week, a measles outbreak spans multiple US states and the CDC highlights a rise in syphilis incidents. Fatalities from Group A strep infections have doubled since last year in Canada, and people who inject drugs are at higher risk for hepatitis C and HIV. Investigators are also tracking incident rates over time post-COVID-19 pandemic.

New vancomycin dosing regimens are proposed to improve outcome and minimize toxicity in overweight and obese patients with renal insufficiency.

Study shows both recent and earlier use of these medications significantly heightens the risk.

People who inject drugs (PWID) are at a higher risk for hepatitis C and HIV. A new study examined point of care initiatives and how to better support this population with intervention efforts.

Group A streptococcal infections outbreak nearly doubles fatalities from the previous year.